Free shipping on all orders over $ 500

JNJ-26854165

Cat. No. M2068

All AbMole products are for research use only, cannot be used for human consumption.

JNJ-26854165 Structure
Synonym:

Serdemetan

Size Price Availability Quantity
5mg USD 70  USD70 In stock
10mg USD 110  USD110 In stock
50mg USD 390  USD390 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

JNJ-26854165 (Serdemetan) is a p53-activating agent with antiproliferative activity in various p53 wild-type (WT) tumor cell lines. JNJ-26854165 inhibited clonogenic survival in all cell lines, but in a lower extent in p53-null-HCT116. JNJ-26854165 also inhibited proliferation, capillary tube formation and migration of HMEC-1 cells. JNJ-26854165 demonstrated cytotoxic activity in vitro. In vivo, JNJ-26854165 (Serdemetan) caused a greater than additive increase in tumor growth delay. JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts in vivo. JNJ-26854165 (Serdemetan) treatment at 0.25μM in H460 and at 5μM in A549 cells resulted in a sensitivity-enhancement ratio of 1.18 and 1.36, respectively. JNJ-26854165 treatment induced p53-mediated apoptosis in acute leukemia cells with wild-type p53, in which p53 rapidly drives transcription-independent apoptosis followed by activation of a transcription-dependent pathway. JNJ-26854165 accelerated the proteasome-mediated degradation of p21 and antagonized the transcriptional induction of p21 by p53. JNJ-26854165 is currently being evaluated in Phase I clinical trials.

Chemical Information
Molecular Weight 328.41
Formula C21H20N4
CAS Number 881202-45-5
Solubility (25°C) DMSO 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Chargari C, et al. Cancer Lett. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts.

[2] Smith MA, et al. Pediatr Blood Cancer. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

[3] Kojima K, et al. Mol Cancer Ther. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias.

Related p53 Products
PK095 

PK095 is a p53 mutant stabilizer.

HLI373 

HLI373 is an efficacious Hdm2 inhibitor.

Cjoc42 

Cjoc42 is a compound capable of binding to gankyrin.

MDM2-IN-1 

MDM2-IN-1 is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration.

p53-MDM2-IN-4 

p53-MDM2-IN-4 is an inhibitor of p53-MDM2/X protein interaction, with a Ki value of 3.079 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: JNJ-26854165, Serdemetan supplier, p53, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.